Finance

Lists
4142:TPE
Adimmune Corp
16,15 NT$
-0,62%
(-0,10) 1D
18 ნოე, 13:17:57 GMT+8  ·   TWD
All symbols
SymbolPriceChange% Change
Generating top insights for 4142...
Open
16,35 NT$
High
16,55 NT$
Low
16,00 NT$
Mkt. cap
6,94 მლრდ.
Avg. vol.
1,09 მლნ.
Volume
501,80 ათ.
52-wk high
21,50 NT$
52-wk low
15,65 NT$
EPS
-0,34 NT$
Shares outstanding
235,29 მლნ.
No. of employees
564
Open
16,35 NT$
High
16,55 NT$
Low
16,00 NT$
Mkt. cap
6,94 მლრდ.
Avg. vol.
1,09 მლნ.
Volume
501,80 ათ.
52-wk high
21,50 NT$
52-wk low
15,65 NT$
EPS
-0,34 NT$
Shares outstanding
235,29 მლნ.
No. of employees
564
News stories
From web sources and news partners
Profile
Adimmune Corporation is a Taiwanese pharmaceutical company engaged in the research, development, manufacturing, and sales of medicines and vaccines for both humans and animals. Its products are supplied to both local and international markets. Founded in 1965 and headquartered in Tanzi District, Taichung, it has a market cap of US$230 million, 564 employees and annual sales of $106 million as of 2026. Adimmune continues to seek expansion its role in the regional pharmaceutical and vaccine industry through international collaborations. In January 2021, Adimmune Corporation announced a partnership with Sam Chun Dang Pharm to jointly develop an injectable medication used to treat macular disease. In July 2021, the company announced that its first overseas manufacturing site will be situated in the Special Economic Zone in East Java, Indonesia, aiming to launch clinical trials for its COVID-19 vaccine in Indonesia early 2022. In August 2021, Adimmune Corporation signed a memorandum of understanding with Becton, Dickinson and Company to strengthen its international pharmaceutical collaboration. Wikipedia
About Adimmune Corp
CEO-
Employees564
Founded1965
Headquarters-
SectorHealth Care
Industry-
Previous reportsAll values in TWD
Loading Previous Earnings...
Revenue
Net income
All values in TWD
სექ. 2025
დეკ. 2025
მარ. 2026
ივნ. 2026
Revenue
475,32 მლნ.
745,46 მლნ.
82,32 მლნ.
66,76 მლნ.
Cost of goods sold
390,92 მლნ.
376,00 მლნ.
156,87 მლნ.
129,59 მლნ.
Cost of revenue
390,92 მლნ.
376,00 მლნ.
156,87 მლნ.
129,59 მლნ.
Research and development expenses
38,46 მლნ.
74,68 მლნ.
45,44 მლნ.
30,55 მლნ.
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
95,91 მლნ.
94,80 მლნ.
79,22 მლნ.
79,34 მლნ.
Operating expense
146,27 მლნ.
197,18 მლნ.
124,66 მლნ.
109,88 მლნ.
Total operating expenses
537,18 მლნ.
573,18 მლნ.
281,54 მლნ.
239,47 მლნ.
Operating income
-61,86 მლნ.
172,28 მლნ.
-199,22 მლნ.
-172,71 მლნ.
Other non operating income
249,00 ათ.
10,40 მლნ.
710,00 ათ.
2,18 მლნ.
EBT including unusual items
-38,56 მლნ.
200,77 მლნ.
-200,47 მლნ.
-172,95 მლნ.
EBT excluding unusual items
-38,56 მლნ.
200,30 მლნ.
-198,95 მლნ.
-172,95 მლნ.
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-18,26 მლნ.
220,42 მლნ.
-185,54 მლნ.
-160,23 მლნ.
Net profit margin
-3,84%
29,57%
-225,41%
-240,02%
Earnings per share
-
-
-
-
Interest and investment income
2,85 მლნ.
9,92 მლნ.
3,10 მლნ.
6,47 მლნ.
Interest expense
-8,82 მლნ.
-10,40 მლნ.
-7,40 მლნ.
-6,95 მლნ.
Net interest expenses
-5,97 მლნ.
-475,00 ათ.
-4,30 მლნ.
-480,00 ათ.
Depreciation and amortization charges
-
-
-
-
EBITDA
-19,68 მლნ.
219,90 მლნ.
-156,74 მლნ.
-128,36 მლნ.
Gain or loss from assets sale
-
-3,00 ათ.
-
-
Upcoming events
AI content may include mistakes. Learn more
Google აპები